[Pharmacokinetics Study on Curcumin Hydroxypropyl-β-Cyclodextrin Phospholipid Complex in Rats].
OBJECTIVE
To compare the in vivo pharmacokinetics of curcumin hydroxypropyl-β-cyclodextrin phospholipid complex, curcumin hydroxypropyl-β-cyclodextrin and curcumin phospholipid complex, and to discuss the advantage of hydroxypropyl-β-cyclodextrin phospholipid complex as carrier.


METHODS
Drawing blood after SD rats were oral administered with the above preparations and free drug at 50 mg/kg( corresponding to curcumin) , and the blood concentration were determined by HPLC.


RESULTS
The AUC0-∞ of curcumin hydroxypropyl-β-cyclodextrin phospholipid complex was(1 126. 20 ± 323. 24) g/(L . h), which was 5. 89, 1. 49 and 1. 17 times as curcumin (191. 08 ± 43. 27) µg/( L . h), curcumin phospholipid complex(754. 93 ± 55. 33) µg/(L . h), curcumin hydroxypropyl-β- cyclodextrin(961. 21 ± 253. 65) µg/(L . h).


CONCLUSIONS
The curcumin hydroxypropyl-β-cyclodextrin phospholipid complex has a better absorption property than curcumin phospholipid complex and curcumin hydroxypropyl-β-cyclodextrin, which is more beneficial to improve the bioavailability.
Jian-chun
JC
Luo
Xue-yuan
XY
Hu
Jian-yong
JY
Wu
De-zhang
DZ
Zhao
Jing-qing
JQ
Zhang
D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000818:Animals; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D003474:Curcumin / Q000737:chemistry*; D010743:Phospholipids / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D047392:beta-Cyclodextrins / Q000493:pharmacokinetics*
D010743:Phospholipids; D047392:beta-Cyclodextrins; D000073738:2-Hydroxypropyl-beta-cyclodextrin; D003474:Curcumin